Share Name Share Symbol Market Type Share ISIN Share Description
Plethora LSE:PLE London Ordinary Share GB00B06GL868 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 3.375p 0 01:00:00
Bid Price Offer Price High Price Low Price Open Price
0.00p 0.00p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.86 -0.34 -3.20 27.8

Plethora Solutions (PLE) Latest News

Real-Time news about Plethora (London Stock Exchange): 0 recent articles
More Plethora Solutions News
Plethora Solutions Takeover Rumours

Plethora Solutions (PLE) Share Charts

1 Year Plethora Solutions Chart

1 Year Plethora Solutions Chart

1 Month Plethora Solutions Chart

1 Month Plethora Solutions Chart

Intraday Plethora Solutions Chart

Intraday Plethora Solutions Chart

Plethora Solutions (PLE) Discussions and Chat

Plethora Solutions Forums and Chat

Date Time Title Posts
29/4/201919:57Regent Pacific/Plethora-
30/1/201811:56PHILIPS: A pearl of a Smart Card Play if you adore Oysters.62
31/12/201708:32TARA BUYS PLETHORA FOR PLEASURE [9.175p] 15/01/20109,803
01/4/201611:59Regent Pacific share certificate1

Add a New Thread

Plethora Solutions (PLE) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Plethora Solutions trades in real-time

Plethora Solutions (PLE) Top Chat Posts

liquid millionaire: How/where etc does one keep up to date with the PLE share price in HK?
lagosboy: In fairness the expected timelines were laid out in an earlier RNS. My take, for what its worth, is that pretty early on they got a heads up from the technical guys that the cannister issue was solvable and hence they bought out Sharwood back in June. As soon as the batches were complete for stability testing, they had the green light to go ahead with an offer from RP without exposing themselves to lawsuits. The purpose of the offer is solely to get access to the cash within RP to speed up developments on all fronts. A stand alone RNS may well have helped the Ple share price but there was no new development beyond what the company had already released in an RNS. Moving into an offer period means one has to tread very carefully in terms of information disseminated, especially if it could be viewed as an attempt to manipulate the share price. Given the cannister issue is likely resolved, and whilst there always remains a slight possibility that it fails the six month stability test, now would seem to be a very good opportunity to buy. Whilst an offer would be welcome at the right price, JM and his team are focused on the end game, more licence deals and cracking the US. My only unanswered concern is why have Baker Brothers been selling?
zangdook: which is still a fair premium to the current PLE share price.
big_cat: This is from Simon Thompson in Investors Chronicle this morning .... Plethora gets a boost The other news that caught my eye was the bid approach from Hong Kong-listed Regent Pacific (Hong Kong Stock Code: 575), the investment vehicle of Jim Mellon, for Aim-traded Plethora Solutions (PLE: 5p), a UK-based speciality pharmaceutical company dedicated to the development and marketing of products for the treatment and management of urological disorders. Plethora's principal product is PSD502™, a prescription treatment for male premature ejaculation that obtained marketing authorisation from the European Commission in November 2013. Regent Pacific and its concert parties together already hold 29.88 per cent of Plethora's issued ordinary share capital and their indicative offer has been pitched at 15.7076 new Regent Pacific shares for each Plethora share. On the basis of Regent Pacific’s share price of HK$0.10, and using a sterling to Hong dollar exchange rate of £1:HK$11.71, the potential offer values each Plethora share at 13.4p, the company’s issued ordinary share capital at £110m and fully diluted share capital (excluding the out-of-money outstanding options and warrants) at £131m. This represents a thumping premium to Plethora’s sagging share price of 2.75p prior to news of the offer being made. But before you get too excited it’s worth flagging up that there is no cash element and Regent Pacific only has a market value of £30m. That’s less than Plethora’s market value of £41m and explains why there is such a big difference between the implied offer price of 13.4p a share and Plethora’s current share price of 5p. Still it’s fair to assume that a formal bid will be made as Regent Pacific has since received letters of intent from investors controlling 10.96 per cent of the Plethora’s issued share capital, so now has almost 41 per cent of the equity backing the bid. Clearly, it’s not going to be possible for everyone to buy Plethora’s shares in the London market at 5p, sit back and wait for the formal bid to be made, and then sell your Regent Pacific shares immediately at 13.4p in Hong Kong. If every investor attempts to do this then Regent Pacific’s share price will fall sharply given that it is issuing 15.4bn shares or more than four times its current issued share capital. That said, one of the reasons Plethora’s shares were so weak in the first place was down to the fact that the company is short of funds, so the price has been depressed due to financial distress. Eliminate this factor and a higher valuation is warranted. Prospects for PSD502™ Indeed, Plethora only has cash balances of £1m, and guidance is that commercial operations under its current operating plans will face a “significant negative impact in January 2016 in the absence of further funding being available to Plethora.” Regent Pacific has net cash and unpledged listed equity securities worth about £8.9m on its balance sheet which it can use in order to develop and commercialise PSD502™, and meet the substantial funding needs of Plethora in the near future. Moreover, it is desirable to progress with planned expenditure in key areas which support the development and commercialisation of PSD502™, such as manufacturing of a reduced fill can for the product, and research and development spend associated with a New Drug Application approval with the US regulator. A key objective is to obtain EU approval by 30 June 2016 for its reduced fill product, such that Plethora can obtain the variation payment of €6m from its European licence partner Recordati (REC:MIL), a €4.8bn pharmaceutical group listed on the Milan Stock Exchange, in preparation for its commercial launch in the EU; and firming up licenses for other territories too. Plethora’s board has had discussions with partners in Latin America, Asia Pacific and South Africa, and with a multi-national pharmaceutical company for 'out licensing' the grant of rights by Plethora in respect of PSD502™ for countries in the Middle East. In all cases the parties have entered into non-binding heads of terms and have moved into discussions on the licence agreement which anticipate an up-front payment to Plethora followed by additional payments upon the achievement of certain milestones plus royalties linked to sales. However, before negotiations can complete a reduced fill product for PSD502™has to be developed and manufactured under good manufacture practice conditions. And for that Plethora needs more funding. This is where Regent Pacific comes in. Implied value of Plethora Clearly, Mr Mellon and his concert party can see great potential in PSD502™otherwise the bid would not have been pitched at such an elevated level. Indeed, in the first half of this year, Regent Pacific acquired certain rights and obligations under a promissory note, worth up to £4.58m, in respect of services provided to Plethora in relation to out-licensing of PSD502™ under the Recordati agreement. Furthermore, it’s worth noting that Plethora self-developed this product and had not capitalised any of the costs incurred, nor any of the future value it may derive. Regent Pacific, with the assistance of a professional independent valuation expert, Jones Lang LaSalle Corporate Appraisal and Advisory, determined the fair value of PSD502™ based on the “relief from royalty method” to be in the region of US$253m, or £167m at current exchange rates. This explains why Regent Pacific’s indicative offer values Plethora’s equity north of £100m. Only time will tell whether this is a fair valuation or not. Frankly, whether or not PSD502™ is a success is not the issue here. I am far more concerned as to what will happen to Regent Pacific’s share price if it launches a formal bid and Plethora shareholders are then issued with a slug of equity. Realistically I can see the price in Hong Kong soften, but certainly not deflate by 60 per cent which is the implied discount in Plethora’s share price. In fact, I reckon that if Regent Pacific launches a bid there could be upwards of 50 per cent upside to Plethora’s current share price of 5p. The interest of Hong Kong investors is being aroused by the potential acquisition too which explains why Regent Pacific’s share price has perked up since news of its bid approach emerged. At around the 5p level, Plethora shares are worth having a small interest in. Speculative buy.
tsmith2: Plethora (PLE) was a company that I was only vaguely aware of up until last week when a potential takeover bid was made for it. Up until then this AIM-listed pharmaceutical company, whose main product is a premature ejaculation treatment, had been trading at between 3p and 4 p, but then an offer landed from Hong Kong investment vehicle, Regent Pacific (also listed in Frankfurt but volume there is almost non-existent), that valued Plethora at 12.5p per share. The offer wasn’t quite as random as it might first have appeared as the two companies have close links, and Jim Mellon and his Regent Pacific vehicle, plus other interests he has, own just under 30% of Plethora. The share price rocketed to over 7p on the day of this news, but has since dropped back to the current level of around 5p. That might seem strange until you look at the deal in more detail and see that it is an all-paper offer, with Plethora holders getting 15.7076 Regent shares for every share that they hold. That made it far less certain that the deal will ultimately be worth 12.5p, if and when it is finalised, and many private investors didn’t seem too keen on possibly ending up with Hong Kong listed stock and sold into the spike. Since then we have seen a continued sell-off of Plethora shares – probably partly from people who bought near the top of the spike and then sold because it didn’t hit 12.5p overnight! – and that has included one of the institutional holders, Baker Brothers, selling a small amount of its holding. What we haven’t seen though, and which has surprised me, is any sort of sell off of Regent shares in Hong Kong, where the share price has remained steady at around HK0.1. This suggests to me that Regent investors are keen on the deal and see it as offering value. Currently Regent has cash but is looking for an investment to generate revenue, and Plethora has a finished product but is desperately short of money. Both share prices are at their lowest levels for sometime and have been a lot higher in recent times, so it could be that the market is viewing the combined entity as likely to be far stronger than the sum of the two separate parts. For me this is all about the potential opportunity being offered by the low Plethora price if the deal goes ahead as planned, and I have been buying at just over 5p on that basis – having watched the reaction in Hong Kong before taking a position. I would expect that those who don’t want to end up with Hong Kong listed shares will sell out before any deal is done, but it is also likely that we will see selling pressure on Regent after the deal due to the huge number of new shares issued. Although there are relatively few Plethora shares are in freefloat and a lot of the outstanding warrants won’t come into play – a chunk of those are owned by parties related to Jim Mellon and Regent so can’t be exercised during a bid period, and the ones from the last placing are at 15p so aren’t currently relevant – so we may not see as much of a sell-off of Regent shares as some might be expecting. The Regent price would also have to collapse to around HK0.04 as well to make it equivalent to the current Plethora price of 5p! Should the deal be finalised and go to a vote it should be a formality that it goes through, as the board has recommended it be accepted and Regent has already received a letter of intent from two big holders pledging support through voting rights on over 10% of the shares in issue. There is of course some risk that this could go lower, but from the current level I personally see good risk versus return, whether you are in for a trade or holding until after the deal is done. - See more at: hxxp://
zangdook: I wouldn't assume that PLE share price is "right" and 575 share price is "wrong" and will adjust. The PLE price has been adjusting and will probably continue to do so. Of course, after the merger goes through old PLE holders will make up ~80% of the share register and some of them will be holding on now intending to dump in HK - see Cawkwell - so there may be a correction. But if HK holders of 575 thought there would be a correction downwards they would sell now and buy back later, and through that selling pressure the correction would be brought forward. The low volumes in HK show that there is not selling pressure being absorbed by friends of Jim Mellon in order to keep the share price steady as was suggested above. People are not dumping the stock. In fact there has already been a fairly substantial move upwards in the PLE share price It's met selling pressure from profit-takers, stale bulls, people who don't like the takeover, people who don't want to hold HK stock etc. I would expect a further move up here as the deal becomes more certain and as the sellers sell out. That's just a guess though, I can't predict.
smithie6: Gotab ..imho ...dont base your views on the small rise of share price of Regent ( ..imho...need to try analyse the offer and your part of PLE now & compare with your part of a merged entity & compare pros & cons etc of both.....& if desired seek prof. advice ( !!) NAG. DYOR. With merger or offer news ( & company results or RNS) it is common to see a share price creates viewers and interest...which can lead to buyers... A jump in interest and small price rise in Regent doesnt mean imo that the merger is good for holders of Regent.... or PLE at a specific share price. ( although PLE doubling in price shows imo that mkt thinks its good for PLE....imho...I assume since it hopefully would provide the cash that PLE appears to need) Im not a PLE expert....pharma/medical is not my area. --- Zzz ( snoozebox jumped maybe 50% 1-2 years ago....partly since tipped by Paul then halved in price over later months..) ... My website opened 2 paper shorts on Vislink on rise in price ....closed today (tweeted)...1 went from 60p to 38.2p :-)....and tweeted website short in Fitbug from 18.5p now 2p ! ( & opened 2nd short. 9p).......proof that a rise in price is no gtee that a price will keep going up ! PLE.. Im not saying its a good or bad deal at 15 new shares....just trying to explain a point.. ----- Anyway...the offer has been good for PLE holders over recent days...with jump in value of shares... Twitter @fulltimeinvest
wiseacre: Bearing in mind that Regent shares, much to my surprise, actually appreciated overnight in Hong Kong, the PLE share price performance is hard to fathom. I guess a lot of stale bulls must have dumped the stock but at this level the shares are unaccountably cheap. Even if Regent falls 25% they are still worth 10p a share.
liquid millionaire: All share offer for PLE but the PLE share price should imho be trading nearer to 12.5p offer price.
reestie3: Looking at previous PLE share price movements, this could reverse very quickly upon further marketing news....and shorters will have to close their positions ASAP. Maybe a company RNS is required to reconfirm the positives/benefits achieved to date....this must be the bottom....definately time top top up IMHO.
Plethora Solutions share price data is direct from the London Stock Exchange
Your Recent History
Plethora S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190521 22:42:00